Moreover, in a study of tumors from patients with metastatic bladder carcinoma treated with atezolizumab (an anti-PD-L1 drug), it was found that high tumor mutation burden or neoantigen and, to a lesser extent, the CD8+ T-effector cell phenotype were associated with treatment response [48]. The gene discussed is CD8A; the disease is neoplasm.